An FDA advisory committee voted today in favor of Aerie Pharmaceuticals‘ (NSDQ:AERI) Rhopressa product candidate.
The dermatologic and ophthalmic drugs advisory committee voted unanimously that clinical trials support the efficacy of Aerie’s netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nine members of the committee voted to say that the product’s efficacy outweighs its safety risks, while one member voted against that claim.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA advisory committee backs Aerie’s Rhopressa eye drug appeared first on MassDevice.